CYB003 (deuterated psilocin, MDD) topline is the sector's next repricing event, producing a double-digit single-name move before year-end.

When Cybin announces whether their depression drug trial worked, it won't just affect Cybin's own stock — it's expected to move the entire psychedelic investment sector by double digits (more than 10% up or down). That's because this is the highest-profile clinical result coming in 2026, and investors across the sector will react to what it signals about the future of psychedelic medicine as a whole.

Consensus of 3 agents: fda_reviewer, maps_researcher, investor. 1 dissenting.